Advertisement

Topics

Sage Therapeutics Prices Public Offering of Common Stock

21:00 EST 14 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offeri...

Other Sources for this Article

Investor Contact:
Sage Therapeutics
Paul Cox, 617-299-8377
paul.cox@sagerx.com
or
Media Contact:
Suda Communications LLC
Maureen L. Suda, 585-355-1134
maureen.suda@sagerx.com

NEXT ARTICLE

More From BioPortfolio on "Sage Therapeutics Prices Public Offering of Common Stock"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...